Kornimate/medical-research-clean huggingface dataset:
detection of covid-19 decompensation

Conditions: Covid19

Summary: in this study we will be monitoring for patient events (emergency department admission, hospital admission, admission to an observation unit, or death) and evaluating the feasibility and utility of using pinpointiq in the management of patients with covid-19. vital sign (physiology data) is collected to build a covid decompensation index and contribute data to a covid digital hub supported by the national institutes of health.

this is a prospective, non-randomized, open-label, two-phase design. the primary focus for the study is data collection for index development. this will be done in two phases: the first phase allows for determination of predictor variables that establish the covid-19 decompensation index (cdi) and the second phase establishes performance of the cdi. a participant is considered to have completed the study if he or she completes all phases of the study including the last day of monitoring (day 28).

Eligibility criteria:
inclusion criteria: obtained signed and dated informed consent form patient in the university of illinois health system patient agrees to comply with all study procedures and availability for the duration of the study male or female, aged \> 18 years of age patient diagnosed with covid-19 (positive sars cov2 test) patient agrees to refrain from swimming or taking baths (any activity that submerges the biosensor in water for any period). showering is okay. exclusion criteria: known allergic reactions to components of the hydrocolloid gel adhesives subject has cognitive or physical limitations that, in the opinion of the investigator, limits the subject's ability to fully follow study procedures cognitive ability, in the opinion of the investigator, that limits the patient's ability to use the biosensor and smartphone consistent with study requirements. does not speak or read english or spanish
treatment of hepatitis c virus infection with generic sofosbuvir/ledipasvir in iranian patients

Conditions: Hepatitis C

Summary: hepatitis c virus (hcv) infection with around 0.5% and 2.2% prevalence in iran and world is one of the public health problems resulting in chronic liver disease, cirrhosis and hepatocellular carcinoma. all cases of chronic hcv infections are candidates of treatment to prevent advanced liver diseases. the previous pegylated-interferon and ribavirin therapy was not efficient in all cases and results in numerous number of side-effects. introduction of direct acting antiviral agents (daas) such as sofosbuvir and ledipasvir make the eradication of hcv possible however these regimens are not affordable and available in developing countries. the generic daas are manufactured in many of these countries such as iran to provide the treatment with reasonable price.


Eligibility criteria:
inclusion criteria: * chronic hcv infection * \>18 years old exclusion criteria: * hiv co-infected * liver transplanted * receiving drugs with suspected interactions
minipooled-ivig in primary immunodeficiency disease

Conditions: Primary Immunodeficiency

Summary: 1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( mp-ivig) 2. study the safety and efficacy of a newly developed preparation of mp-ivig in children with primary immunodeficiency (pid) : * adverse reaction of mp-ivig(anaphylaxis and haemolysis)( no or mild or moderate) * prevention of severe bacterial infection * improvement of general health(weight gain and mentality) * integration in to social live 3. compare the efficacy of mp-ivig to standard ivig in children with primary immunodeficiency (pid).

primary immunodeficiency diseases (pid) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. clinical descriptions have already been made for more than 200 pids, for which over 150 forms of pid have been molecularly characterized . a population prevalence of diagnosed pid in the united states at approximately 1 in 1,200 persons. a part from local registration in some centres there is no national registry of pid in egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown . an increasing number of pid are recognized, and effective treatments are possible. early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients . immunoglobulin g (igg) is an essential plasma derived medicine that is lacking in developing countries .igg shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. a simple and practical method for producing igg from normal plasma collected in developing countries is needed to provide better, faster access to igg for patients . magdy el-ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. they developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (s/d-f) plasma producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool s/d-f cryoprecipitate to treat bleeding disorders.

Eligibility criteria:
inclusion criteria: * age group: children patients under 18 years. * the study will include patient diagnosed as primary immunodeficiency disease (pid) in assiut university hospital on standard ivig therapy. exclusion criteria: * patient has scid. * patient with history of severe ivig side effect. * patient with severe immunodeficiency and has severe disseminated infection. * patient with renal impairment * patient with hepatic cell failure * patient with endocrinal abnormalities * patient with secondary immunodeficiency diseases
irritable bowel syndrome (ibs) treatment with h1-receptor antagonists

Conditions: Irritable Bowel Syndrome

Summary: purpose: to evaluate the efficiency of irritable bowel syndrome (ibs) patients treatment with the h1-receptor antagonist ebastine. design: double blind randomized placebo controlled trial. ibs patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization). end points: end point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.


Eligibility criteria:
inclusion criteria: * irritable bowel syndrome (rome iii criteria) * age 18-65 years exclusion criteria: * medication: antidepressants or h1-receptor antagonists * pregnancy, breast feeding * co-morbidity: severe kidney- and/or liver disease

Keywords: visceral hypersensitivity mast cells
diagnostic and prognostic value of reticulated platelet fraction in ventilator-associated pneumonia (replay-vap)

Conditions: Ventilator-Associated Pneumonia

Summary: ventilator-associated pneumonia (vap) is a serious infection that occurs in patients who have been on mechanical ventilation for more than 48 hours in the intensive care unit (icu). early and accurate diagnosis is critical to reduce complications and improve outcomes. this prospective observational study aims to evaluate the diagnostic and prognostic value of reticulated platelet fraction (rp%) in patients diagnosed with vap. blood samples will be taken as part of routine care, and rp% levels will be analyzed using a standard hematology analyzer. the study will investigate whether rp% can help identify vap earlier and predict outcomes such as mortality and response to antibiotics.


Eligibility criteria:
inclusion criteria: * age 18 years or older * receiving mechanical ventilation for more than 48 hours * diagnosed with ventilator-associated pneumonia (vap) according to clinical, radiologic, and laboratory criteria exclusion criteria: * diagnosis of pneumonia upon icu admission * pneumonia as the primary reason for initiation of mechanical ventilation * mechanical ventilation duration less than 48 hours * pregnant or breastfeeding patients * presence of chronic inflammatory conditions, hematologic disorders, malignancy, autoimmune disease, or immunosuppressive/chemotherapy/radiotherapy treatment within the past 4 weeks
evaluation of prevecol's efficiency as a second line method for the early colorectal cancer detection

Conditions: Screening for Colon Cancer; Blood Samples; Survey and Questionnaire; Colorectal Carcinoma; Colon Adenocarcinoma; Precancerous Lesion of Colon

Summary: the objective of this low-risk interventional study is to evaluate whether the prevecol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive fobt result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. the main aims to be answered are: * values of efficacy, efficiency, impact and safety of prevecol. * values of preferences of participants for screening methods. * values of prems into screening programme. participants will provide a blood sample prior to a screening colonoscopy, and complete two questionnaires. they will give their sample, information and clinical data to the investigator or health care personnel.


Eligibility criteria:
inclusion criteria: * participants ages from 50 to 69 years (both included) at the time of informed consent signed. * participants should sign an informed consent. they must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form. * participants with a positive result of fit/fobt analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme. * participants asymptomatic, average risk for crc. average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of crc (first degree relatives). exclusion criteria: * participants who have developed any another type of cancer in the 5 years prior to their participation in the study. * participants who have previously received chemotherapy or radiotherapy (5 years). * participants previously or currently diagnosed with familiar adenomatous polyposis or lynch syndrome or inflammatory bowel disease. * inadequate intestinal preparation for colonoscopy with bbps score ≤1 in any colon section, excluding diagnostic of crc. * participants who have undergone polypectomy in the previous 5 years. * hemolysis of blood sample or absence of blood sample. * participants who are arrested at judicial or official request * participants who are in a dependent personal or non-medical relationship with the sponsor or the investigator.

Keywords: colorectal cancer screening programme liquid biopsy second line questionnaire
telerehab to restore upper limb function in people with chronic tbi

Conditions: Traumatic Brain Injury; Upper Extremity Dysfunction; Disability Physical

Summary: the study aims to inform the subsequent large-scale clinical trial focused on using telerehabilitation techniques and technologies to improve upper limb function and quality of life.

upper limb (ul) function is often impaired and not fully recovered after moderate-to-severe traumatic brain injury (tbi), leading to devastating consequences and reducing quality of life. clinicians have been encouraged to include ul rehabilitation, but existing evidence is insufficient to inform specific treatments for the tbi population. there is urgency to broaden the scientific evidence critical to advancing ul rehabilitation for tbi survivors, especially those living in the community with chronic ul impairment. the study will examine two ul exercise programs through tele-rehabilitation (telerehab) techniques. both programs are focused on functional tasks and daily activities. one program is implemented directly in the real-life home environment, the home-based arm and hand exercise (hahe) program. the other program is delivered through simulated real-world scenarios, the exercise video game (exergame) program. the hahe program consists of ul exercises based on real-life activities that involve materials and objects readily available at home or easily obtained in regular stores. the exergame program packages ul exercises into game-like activities delivered through a non-immersive virtual reality device. individuals with chronic ul impairment after moderate-to-severe tbi will participate in the proposed study. they will be randomly assigned to the hahe or the exergame program. patients will complete 30 sessions of the assigned program over 6 weeks at home, with no immediate supervision. an occupational therapist will review the progress, assist in goal setting, and provide consultation to patients at the beginning of each week via a video call. the investigators will determine which of the programs is effective, and whether the programs lead to similar or different outcomes.

Eligibility criteria:
inclusion criteria: * time post injury \> 12 months * moderate-to-severe tbi * one upper limb (ul) is more affected than the other, and the participant reports impaired ul function because of the more affected limb. * the more affected limb is at the brunnstrom stage 3, 4, or 5 of arm recovery . * meeting the following technology requirements: possessing and using a smartphone, internet connection at home, and having a tv at home exclusion criteria: * \< 18 years old at the time of injury * a history of previous neurological disorder * a history of substance abuse requiring inpatient treatment * the more affected limb is at the brunnstrom stage 1, 2, 6, or 7 of arm recovery. * experiencing severe pain during the brunnstrom stage evaluation * active subluxation of the shoulders * living outside of the 50-mile radius of kessler foundation (west orange, nj)

Keywords: upper limb telerehabilitation
improving platelet activity for cerebral hemorrhage treatment - ddavp proof of concept

Conditions: Intracerebral Hemorrhage

Summary: the investigators intend to show that ddavp improves platelet activity from baseline to 60 minutes after treatment start.


Eligibility criteria:
inclusion criteria: * spontaneous intracerebral hemorrhage as documented by head ct scan * documented regular aspirin use or verifynow-asa result of ≤ 550 aspirin reaction units (aru), indicating anti-platelet medication exclusion criteria: * international normalized ratio (inr) of ≥ 1.7 from coagulopathy or warfarin use * history of von willebrand disease * pregnancy * known hypersensitivity to ddavp or desmopressin * active cardiovascular disease or unstable angina * hyponatremia or history of hyponatremia * current or historical deep venous thrombosis or pulmonary embolism

Keywords: intracerebral hemorrhage platelets
tobacco dependence in breast cancer patients trial of varenicline (chantix)

Conditions: Breast Cancer; Tobacco Dependence

Summary: breast cancer patients who smoke, are at greater risk for treatment complications. the purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. they will compare two ways to help people quit smoking. some patients will receive varenicline, a prescription medicine also known as chantix,®. other patients will receive a placebo drug. a placebo is an inactive substance that contains no medicine. all patients will receive smoking cessation counseling provided by our tobacco treatment specialists. they hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.


Eligibility criteria:
inclusion criteria: * msk patients diagnosed with breast cancer or have a mass suspicious of breast cancer at the time of enrollment, as per clinician judgment or emr; * self-reported current cigarette smoker (defined as daily smoking in the past seven days) * advised to quit smoking by their msk physician and willing to receive smoking cessation counseling and treatment; as per self report * fluent in english exclusion criteria: * patients less than 18 years of age because the safety and efficacy of varenicline have not yet been tested in children; * evidence of any known or suspected medical contraindications for use of varenicline (e.g., recent (within past two months) cardiovascular instability (including myocardial infarction or unstable angina; uncontrolled hypertension, significant neurological sequelae of cerebrovascular disease, or severe congestive heart failure (new york heart association class iii or iv), severe chronic obstructive pulmonary disease; uncontrolled gastrointestinal, hepatic, or endocrine disease; or severe renal impairment. * self-reported evidence of significant psychiatric history (e.g., schizophrenia, unstable bipolar disorder, panic disorder, untreated major depression) sufficient, in the investigators' judgment, to preclude participation in the clinical trial; * self-reported evidence of recent substance abuse or heavy alcohol use (\> 14 drinks weekly) in the last 6 months; * self-reported recent use (in the past 30 days) or planned use of nicotine replacement therapy (nrt) or other fda approved cessation pharmacotherapy (bupropion); * pre-menopausal women who are pregnant as per emr * women who are breast-feeding as per self-report.

Keywords: placebo varenicline (chantix) self-reported cigarettes smokers smoking cessation 11-136
effect of peritoneal lavage with clindamycin-gentamicin solution on postoperative colorectal cancer infection in elective surgery

Conditions: Surgical Site Infection

Summary: intrabdominal antibiotic irrigation will reduce wound and intrabdominal infection.

a prospective, randomized study was performed between january and december 2010. patient inclusion criteria were a diagnosis of colorectal neoplasms and plans to undergo an elective curative surgery. patients were divided into 2 groups: group 1 (intra-abdominal irrigation with normal saline) and group 2 (intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin). the occurrence of wound infections and intra-abdominal abscesses were investigated. following the anastomosis, a microbiological sample of the peritoneal surface was obtained (sample 1). a second sample was collected following an irrigation with normal saline (sample 2). finally, the peritoneal cavity was irrigated with a gentamicin-clindamycin solution and a third sample was obtained (sample 3).

Eligibility criteria:
inclusion criteria: * diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims. exclusion criteria: * preoperative diagnosis of chronic renal failure, because of the risk of nephrotoxicity associated with intraperitoneal gentamicin absorption * an anastomotic leak in the postoperative course

Keywords: intra-abdominal abscess wound infection colorectal surgery
il-17 levels in intrahepatic cholestasis of pregnancy

Conditions: Intrahepatic Cholestasis of Pregnancy

Summary: the aim of this study is to investigate maternal and fetal serum il-17 levels in pregnant women with intrahepatic cholestasis of pregnancy and to find out if th-17 cells have a role in progress of intrahepatic cholestasis of pregnancy.

intrahepatic cholestasis of pregnancy (icp) is the most prevalent pregnancy-specific liver disease. it occurs mainly in the second or third trimester of pregnancy. it typically resolves after delivery spontaneously but it is associated with an increased risk of adverse fetal outcomes. the cause of icp is heterogeneous, pathophysiology is poorly understood and therapies have been empiric. genetic predispositions, environmental influences, dietary factors and hormonal influences have been studied and cited in the literature. comparing with placebo, ursodeoxycholic acid (udca) has been shown improvement in treatment of pruritus in previous studies. s-adenosylmethionine, guar gum, activated charcoal, dexamethasone, cholestyramine, etc. are not effective in the treatment of symptoms. cd4+ t cells are an essential regulators of immune responses and inflammatory diseases. they are also called chief of orchestra cells of immune system. the balance between t helper-(th)1, th-2 and th-17 cells and their cytokinergic interaction are crucial for the response of the organism. th17 and its specific cytokine il-17 are responsible for pathogenesis of autoimmune diseases as autoimmune uveitis, experimental autoimmune encephalomyelitis in animal models and potentially also in human autoimmune diseases such as multiple sclerosis, crohn's disease, rheumatoid arthritis, psoriasis, primary biliary cirrhosis. recently, il-17 targeted therapies (secukinumab, ixekizumab and brodalumab) are being studied in phase iii clinical trials to evaluate their overall efficacy and safety for certain autoimmune diseases. th-17 levels have been investigated in normal and abnormal pregnancies and results were incompatible with each other. some researchers have said that the level of il-17 increased during pregnancy but the others not. low serum il-17 is associated with premature birth. up-regulation of the il-17 is associated with preeclampsia. k. harada et all. (2009) demonstrated that il-17-positive cells are associated with the chronic inflammation of bile ducts in primary biliary cirrhosis(pbc). also, some authors demonstrated that th-17-related cytokines were increased significantly in patients with pbc. maho ichikawa et all. presented a case of male newborn infant who showed progressive severe cholestasis with selectively high levels of serum il- 17. based on all this information, we decided to investigate maternal and fetal serum il-17 levels of pregnants with icp and the effects of udca therapy on it and find out if th-17 cells have a role in progress of icp.

Eligibility criteria:
inclusion criteria: clinical diagnosis of icp - exclusion criteria: multiple pregnancies known chronic illness

Keywords: cholestasis, pregnant, interleukin 17